OxyContin » Медицинский журнал

Мы профессиональная команда, которая на рынке работает уже более 5 лет и специализируемся исключительно на лучших продуктах.

===============

Наши контакты:

Telegram:

>>>Купить через телеграмм (ЖМИ СЮДА)<<<

===============

____________________

ВНИМАНИЕ!!! Важно!!!

В Телеграм переходить только по ССЫЛКЕ, в поиске НАС НЕТ там только фейки!

Чтобы телеграм открылся он у вас должен быть установлен!

____________________

OxyContin » Медицинский журнал

Medically reviewed by Drugs. Last updated on Oct 17, OXYCONTIN 60 mg and 80 mg tablets, a single dose greater than 40 mg, or a total daily dose greater than 80 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established. Adult patients who are opioid tolerant are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Instruct patients not to pre-soak, lick, or otherwise wet the tablet prior to placing in the mouth \\\\\\\\\\\\[see Warnings and Precautions 5. Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression \\\\\\\\\\\\[see Warnings and Precautions 5. While useful tables of opioid equivalents are readily available, there is substantial inter-patient variability in the relative potency of different opioids. Close observation and frequent titration are warranted until pain management is stable on the new opioid. The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. Methadone has a long half-life and can accumulate in the plasma. Although there has been no systematic assessment of such conversion, start with a conservative conversion: substitute 10 mg of OXYCONTIN every 12 hours for each 25 mcg per hour fentanyl transdermal patch. The following dosing information is for use only in pediatric patients 11 years and older already receiving and tolerating opioids for at least five consecutive days. Table 1, based on clinical trial experience, displays the conversion factor when switching pediatric patients 11 years and older under the conditions described above from opioids to OXYCONTIN. There is substantial inter-patient variability in the relative potency of different opioid drugs and formulations. Example conversion from a single opioid e. Step 3 : Close observation and titration are warranted until pain management is stable on the new opioid. If using asymmetric dosing, instruct patients to take the higher dose in the morning and the lower dose in the evening. Continually reevaluate patients receiving OXYCONTIN to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and adverse reactions, as well as monitoring for the development of addiction, abuse and misuse \\\\\\\\\\\\[see Warnings and Precautions 5. During chronic therapy, periodically reassess the continued need for the use of opioid analgesics. Patients who experience breakthrough pain may require a dosage adjustment of OXYCONTIN or may need rescue medication with an appropriate dose of an immediate-release analgesic. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions. There are no well-controlled clinical studies evaluating the safety and efficacy with dosing more frequently than every 12 hours. For geriatric patients who are debilitated and not opioid tolerant, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage cautiously \\\\\\\\\\\\[see Use in Specific Populations 8. For patients with hepatic impairment, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage carefully. Monitor for signs of respiratory depression, sedation, and hypotension \\\\\\\\\\\\[see Use in Specific Populations, 8. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic \\\\\\\\\\\\[see Warnings and Precautions 5. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. OxyContin reviews. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to Drugs. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. We comply with the HONcode standard for trustworthy health information - verify here. Skip to Content. Initial Dosage in Pediatric Patients 11 Years and Older The following dosing information is for use only in pediatric patients 11 years and older already receiving and tolerating opioids for at least five consecutive days. Consider the following when using the information in Table 1. This is not a table of equianalgesic doses. Doing so will result in an over-estimation of the dose of the new opioid and may result in fatal overdose. For example, for high-dose parenteral morphine, use 1. For pediatric patients on a regimen of more than one opioid, calculate the approximate oxycodone dose for each opioid and sum the totals to obtain the approximate OXYCONTIN daily dosage. Follow the patient closely during conversion from transdermal fentanyl to OXYCONTIN If using asymmetric dosing, instruct patients to take the higher dose in the morning and the lower dose in the evening. Dosage Modifications in Geriatric Patients who are Debilitated and not Opioid-Tolerant For geriatric patients who are debilitated and not opioid tolerant, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage cautiously \\\\\\\\\\\\[see Use in Specific Populations 8. Dosage Modifications in Patients with Hepatic Impairment For patients with hepatic impairment, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage carefully. Drug Status Rx. Availability Prescription only. Purdue Pharma LP. Drug Class. Narcotic analgesics. Related Drugs. OxyContin Images. Subscribe to our newsletters. FDA alerts for all medications. Daily news summary. Weekly news roundup. Monthly newsletter. I accept the Terms and Privacy Policy. Email Address. Explore Apps. About About Drugs. All rights reserved. Conversion Factor.

OxyContin » Медицинский журнал

oxycontine

Medically reviewed by Drugs. Last updated on Oct 17, OXYCONTIN 60 mg and 80 mg tablets, a single dose greater than 40 mg, or a total daily dose greater than 80 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established. Adult patients who are opioid tolerant are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Instruct patients not to pre-soak, lick, or otherwise wet the tablet prior to placing in the mouth \\\\\\\\\\\\\\[see Warnings and Precautions 5. Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression \\\\\\\\\\\\\\[see Warnings and Precautions 5. While useful tables of opioid equivalents are readily available, there is substantial inter-patient variability in the relative potency of different opioids. Close observation and frequent titration are warranted until pain management is stable on the new opioid. The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. Methadone has a long half-life and can accumulate in the plasma. Although there has been no systematic assessment of such conversion, start with a conservative conversion: substitute 10 mg of OXYCONTIN every 12 hours for each 25 mcg per hour fentanyl transdermal patch. The following dosing information is for use only in pediatric patients 11 years and older already receiving and tolerating opioids for at least five consecutive days. Table 1, based on clinical trial experience, displays the conversion factor when switching pediatric patients 11 years and older under the conditions described above from opioids to OXYCONTIN. There is substantial inter-patient variability in the relative potency of different opioid drugs and formulations. Example conversion from a single opioid e. Step 3 : Close observation and titration are warranted until pain management is stable on the new opioid. If using asymmetric dosing, instruct patients to take the higher dose in the morning and the lower dose in the evening. Continually reevaluate patients receiving OXYCONTIN to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and adverse reactions, as well as monitoring for the development of addiction, abuse and misuse \\\\\\\\\\\\\\[see Warnings and Precautions 5. During chronic therapy, periodically reassess the continued need for the use of opioid analgesics. Patients who experience breakthrough pain may require a dosage adjustment of OXYCONTIN or may need rescue medication with an appropriate dose of an immediate-release analgesic. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions. There are no well-controlled clinical studies evaluating the safety and efficacy with dosing more frequently than every 12 hours. For geriatric patients who are debilitated and not opioid tolerant, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage cautiously \\\\\\\\\\\\\\[see Use in Specific Populations 8. For patients with hepatic impairment, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage carefully. Monitor for signs of respiratory depression, sedation, and hypotension \\\\\\\\\\\\\\[see Use in Specific Populations, 8. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic \\\\\\\\\\\\\\[see Warnings and Precautions 5. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. OxyContin reviews. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to Drugs. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. We comply with the HONcode standard for trustworthy health information - verify here. Skip to Content. Initial Dosage in Pediatric Patients 11 Years and Older The following dosing information is for use only in pediatric patients 11 years and older already receiving and tolerating opioids for at least five consecutive days. Consider the following when using the information in Table 1. This is not a table of equianalgesic doses. Doing so will result in an over-estimation of the dose of the new opioid and may result in fatal overdose. For example, for high-dose parenteral morphine, use 1. For pediatric patients on a regimen of more than one opioid, calculate the approximate oxycodone dose for each opioid and sum the totals to obtain the approximate OXYCONTIN daily dosage. Follow the patient closely during conversion from transdermal fentanyl to OXYCONTIN If using asymmetric dosing, instruct patients to take the higher dose in the morning and the lower dose in the evening. Dosage Modifications in Geriatric Patients who are Debilitated and not Opioid-Tolerant For geriatric patients who are debilitated and not opioid tolerant, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage cautiously \\\\\\\\\\\\\\[see Use in Specific Populations 8. Dosage Modifications in Patients with Hepatic Impairment For patients with hepatic impairment, start dosing patients at one-third to one-half the recommended starting dosage and titrate the dosage carefully. Drug Status Rx. Availability Prescription only. Purdue Pharma LP. Drug Class. Narcotic analgesics. Related Drugs. OxyContin Images. Subscribe to our newsletters. FDA alerts for all medications. Daily news summary. Weekly news roundup. Monthly newsletter. I accept the Terms and Privacy Policy. Email Address. Explore Apps. About About Drugs. All rights reserved. Conversion Factor.

OxyContin Dosage

Купить экстази Бразилия

Амфетамин купить Монастир

Купить ганджубас закладкой Краснодар

Купить закладку гашиша Архангельская область

Купить меф Алматы

Купить Ганджа Болохово

Купить закладку кокса Кемер

Купить Гречка Кириши

OxyContin » Медицинский журнал

oxycontine

OxyContin Dosage

Report Page